Literature DB >> 16896642

Persistent B-cell depletion after rituximab for thrombocytopenic purpura.

Gianni Bisogno1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896642     DOI: 10.1007/s00431-006-0222-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  5 in total

1.  Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.

Authors:  Paola Matteucci; Michele Magni; Massimo Di Nicola; Carmelo Carlo-Stella; Caterina Uberti; Alessandro M Gianni
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

2.  Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.

Authors:  Tillmann Taube; Hansjörg Schmid; Harald Reinhard; Arend von Stackelberg; Ursula Schulte Overberg
Journal:  Haematologica       Date:  2005-02       Impact factor: 9.941

3.  Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.

Authors:  Steven D Mawhorter; Anne Sierk; Susan M Staugaitis; Robin K Avery; Ronald Sobecks; Richard A Prayson; Gary W Procop; Belinda Yen-Lieberman
Journal:  Clin Lymphoma Myeloma       Date:  2005-11

4.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

5.  Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.

Authors:  Anna Pusiol; Simone Cesaro; Agostino Nocerino; Giorgio Picco; Luigi Zanesco; Gianni Bisogno
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.183

  5 in total
  4 in total

Review 1.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 2.  Rituximab for children with immune thrombocytopenia: a systematic review.

Authors:  Yi Liang; Lingli Zhang; Ju Gao; Die Hu; Yuan Ai
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 3.  Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?

Authors:  Jennifer Worch; Olga Makarova; Birgit Burkhardt
Journal:  Cancers (Basel)       Date:  2015-01-29       Impact factor: 6.639

4.  Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.

Authors:  Amer M Khojah; Michael L Miller; Marisa S Klein-Gitelman; Megan L Curran; Victoria Hans; Lauren M Pachman; Ramsay L Fuleihan
Journal:  Pediatr Rheumatol Online J       Date:  2019-08-28       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.